Shamburg News · 8-K filed Nov 10, 2026, 4:55 PM EST

Acrivon Therapeutics Hosts EoE Key Opinion Leader Event on New I&I Programs

ACRV · Acrivon Therapeutics, Inc.

  • Other event
  • Reg FD disclosure
  • Materiality: low

On November 10, 2026, Acrivon Therapeutics, Inc. hosted a webcast corporate R&D event with eosinophilic esophagitis key opinion leaders to discuss its new immunology and inflammation programs identified using its AP3 platform. The presentation introduced the ACR-525 JAK1 inhibitor and PKCθ inhibitor preclinical programs and initial development plans in EoE. The presentation is furnished as Exhibit 99.1 under Regulation FD and is not deemed filed.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001193125-26-455669.

Written from the filing by Shamburg Markets. Figures are as reported by the company.